Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.25 CHF | -0.43% | -0.57% | -3.44% |
Apr. 17 | Switzerland's Galenica Issues CHF100 Million Bond Due 2031 | MT |
Mar. 14 | GALENICA : FY23 one-offs shroud decent underlying profitability growth |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.44% | 3.86B | B | ||
+16.17% | 70.45B | C+ | ||
+2.13% | 25.03B | C+ | ||
+7.11% | 8.29B | B | ||
-2.98% | 8.05B | C | ||
-20.55% | 7.97B | B- | ||
+3.91% | 4.62B | B- | ||
+17.12% | 4.25B | B+ | ||
-1.24% | 4.04B | B- | ||
+21.42% | 3.61B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GALE Stock
- Ratings Galenica AG